The Russian Direct Investment Fund (RDIF), Russia’s
sovereign wealth fund, announces agreement on key terms of investments of
RUB100mn in Oncobox, a company developing solutions for cancer diagnosis based
on artificial intelligence (AI).
OECD Green Talks LIVE: Global eChemPortal to information on chemical substancesOECD Environment
To meet public health and environmental objectives for the safe use of chemicals under proper conditions, increasing understanding of chemical hazards and risks is key. By increasing access to data and information, governments and industry can work to reduce – or even eliminate – adverse health effects from exposures to chemicals.
The OECD eChemPortal provides direct access to critical scientific information on chemical substances of regulatory relevance with over 800,000 substance records from 37 databases. The portal allows countries and companies to share work, ensure resource efficiencies, and, subsequently, reduce animal testing.
Gerlinde Knetch (Germany), Jake Sanderson (Canada) and Violaine Verougstraete from Eurometaux shared their experience in improving chemical safety and how the eChemPortal supported this process.
OECD Green Talks LIVE: Global eChemPortal to information on chemical substancesOECD Environment
To meet public health and environmental objectives for the safe use of chemicals under proper conditions, increasing understanding of chemical hazards and risks is key. By increasing access to data and information, governments and industry can work to reduce – or even eliminate – adverse health effects from exposures to chemicals.
The OECD eChemPortal provides direct access to critical scientific information on chemical substances of regulatory relevance with over 800,000 substance records from 37 databases. The portal allows countries and companies to share work, ensure resource efficiencies, and, subsequently, reduce animal testing.
Gerlinde Knetch (Germany), Jake Sanderson (Canada) and Violaine Verougstraete from Eurometaux shared their experience in improving chemical safety and how the eChemPortal supported this process.
OECD Green Talks LIVE: Global eChemPortal to information on chemical substancesOECD Environment
To meet public health and environmental objectives for the safe use of chemicals under proper conditions, increasing understanding of chemical hazards and risks is key. By increasing access to data and information, governments and industry can work to reduce – or even eliminate – adverse health effects from exposures to chemicals.
The OECD eChemPortal provides direct access to critical scientific information on chemical substances of regulatory relevance with over 800,000 substance records from 37 databases. The portal allows countries and companies to share work, ensure resource efficiencies, and, subsequently, reduce animal testing.
Gerlinde Knetch (Germany), Jake Sanderson (Canada) and Violaine Verougstraete from Eurometaux shared their experience in improving chemical safety and how the eChemPortal supported this process.
OECD Green Talks LIVE: Global eChemPortal to information on chemical substancesOECD Environment
To meet public health and environmental objectives for the safe use of chemicals under proper conditions, increasing understanding of chemical hazards and risks is key. By increasing access to data and information, governments and industry can work to reduce – or even eliminate – adverse health effects from exposures to chemicals.
The OECD eChemPortal provides direct access to critical scientific information on chemical substances of regulatory relevance with over 800,000 substance records from 37 databases. The portal allows countries and companies to share work, ensure resource efficiencies, and, subsequently, reduce animal testing.
Gerlinde Knetch (Germany), Jake Sanderson (Canada) and Violaine Verougstraete from Eurometaux shared their experience in improving chemical safety and how the eChemPortal supported this process.
RDIF, Russia’s sovereign wealth fund, and the Foundation of the International Medical Cluster (IMC Foundation, established by the Government of Moscow) announce a partnership aimed at attracting investments in medical projects.
The University Technology Transfer Centre (UTTC)
is part of the University; it provides students, PhD
candidates, and researchers with comprehensive
support at every stage of innovation development
– from the pre-incubation of ideas, to international
patent protection, company start-ups, and
initiating business contacts.
Digital pathology 2018 | Aug 13-14 | Madrid, SpainAyush Lawania
EuroScicon Ltd is glad to invite all the experts in the arena of Pathology to its premier 3rd International Conference on Digital Pathology (Digital Pathology-2018), which is going to be held at Madrid, Spain during August 13-14, 2018. The Theme of the conference is “Digital Pathology Image Analysis: Advancements, Opportunities and Challenges for 21st Century.”
Digital Pathology-2018 brings together the pathologists from both Industry and academia to discuss the advancements and challenges in the broad sector of Pathology but not limited to Molecular Pathology, Cytopathology, Histopathology, Clinical Pathology, Breast Pathology, Immunopathology, Cancer Pathology, Gynaecological pathology, Forensic Pathology, Chemical Pathology and all other allied fields.
So come and be a part of the Europe’s best conference.
OECD Green Talks LIVE: Global eChemPortal to information on chemical substancesOECD Environment
To meet public health and environmental objectives for the safe use of chemicals under proper conditions, increasing understanding of chemical hazards and risks is key. By increasing access to data and information, governments and industry can work to reduce – or even eliminate – adverse health effects from exposures to chemicals.
The OECD eChemPortal provides direct access to critical scientific information on chemical substances of regulatory relevance with over 800,000 substance records from 37 databases. The portal allows countries and companies to share work, ensure resource efficiencies, and, subsequently, reduce animal testing.
Gerlinde Knetch (Germany), Jake Sanderson (Canada) and Violaine Verougstraete from Eurometaux shared their experience in improving chemical safety and how the eChemPortal supported this process.
OECD Green Talks LIVE: Global eChemPortal to information on chemical substancesOECD Environment
To meet public health and environmental objectives for the safe use of chemicals under proper conditions, increasing understanding of chemical hazards and risks is key. By increasing access to data and information, governments and industry can work to reduce – or even eliminate – adverse health effects from exposures to chemicals.
The OECD eChemPortal provides direct access to critical scientific information on chemical substances of regulatory relevance with over 800,000 substance records from 37 databases. The portal allows countries and companies to share work, ensure resource efficiencies, and, subsequently, reduce animal testing.
Gerlinde Knetch (Germany), Jake Sanderson (Canada) and Violaine Verougstraete from Eurometaux shared their experience in improving chemical safety and how the eChemPortal supported this process.
OECD Green Talks LIVE: Global eChemPortal to information on chemical substancesOECD Environment
To meet public health and environmental objectives for the safe use of chemicals under proper conditions, increasing understanding of chemical hazards and risks is key. By increasing access to data and information, governments and industry can work to reduce – or even eliminate – adverse health effects from exposures to chemicals.
The OECD eChemPortal provides direct access to critical scientific information on chemical substances of regulatory relevance with over 800,000 substance records from 37 databases. The portal allows countries and companies to share work, ensure resource efficiencies, and, subsequently, reduce animal testing.
Gerlinde Knetch (Germany), Jake Sanderson (Canada) and Violaine Verougstraete from Eurometaux shared their experience in improving chemical safety and how the eChemPortal supported this process.
OECD Green Talks LIVE: Global eChemPortal to information on chemical substancesOECD Environment
To meet public health and environmental objectives for the safe use of chemicals under proper conditions, increasing understanding of chemical hazards and risks is key. By increasing access to data and information, governments and industry can work to reduce – or even eliminate – adverse health effects from exposures to chemicals.
The OECD eChemPortal provides direct access to critical scientific information on chemical substances of regulatory relevance with over 800,000 substance records from 37 databases. The portal allows countries and companies to share work, ensure resource efficiencies, and, subsequently, reduce animal testing.
Gerlinde Knetch (Germany), Jake Sanderson (Canada) and Violaine Verougstraete from Eurometaux shared their experience in improving chemical safety and how the eChemPortal supported this process.
RDIF, Russia’s sovereign wealth fund, and the Foundation of the International Medical Cluster (IMC Foundation, established by the Government of Moscow) announce a partnership aimed at attracting investments in medical projects.
The University Technology Transfer Centre (UTTC)
is part of the University; it provides students, PhD
candidates, and researchers with comprehensive
support at every stage of innovation development
– from the pre-incubation of ideas, to international
patent protection, company start-ups, and
initiating business contacts.
Digital pathology 2018 | Aug 13-14 | Madrid, SpainAyush Lawania
EuroScicon Ltd is glad to invite all the experts in the arena of Pathology to its premier 3rd International Conference on Digital Pathology (Digital Pathology-2018), which is going to be held at Madrid, Spain during August 13-14, 2018. The Theme of the conference is “Digital Pathology Image Analysis: Advancements, Opportunities and Challenges for 21st Century.”
Digital Pathology-2018 brings together the pathologists from both Industry and academia to discuss the advancements and challenges in the broad sector of Pathology but not limited to Molecular Pathology, Cytopathology, Histopathology, Clinical Pathology, Breast Pathology, Immunopathology, Cancer Pathology, Gynaecological pathology, Forensic Pathology, Chemical Pathology and all other allied fields.
So come and be a part of the Europe’s best conference.
The document summarizes the St. Petersburg International Forum on Pharmacy, Medical Equipment, and Biotechnology held in April 2012. Over 1,000 participants from Russia and abroad attended to discuss innovative development in the pharmaceutical, biotechnology, and medical industries. Key topics included attracting investment, introducing new technologies, and promoting locally made products internationally. The forum featured business programs, exhibitions, tours, and award ceremonies recognizing achievements in these fields. It aimed to facilitate cooperation to advance the regional medical and pharmaceutical cluster in St. Petersburg. Plans were announced for the next IPhEB forum to be held in April 2013.
RusGenDiagnostics Skolkovo Startup Village Pitch SessionElena Denisenko
RusGenDiagnostics develops diagnostic systems for personalized cancer treatment based on tumor molecular profiling using next-generation sequencing and microarrays. Their technology analyzes multiple genomic and transcriptomic alterations to reconstruct the individual tumor profile and evaluate targeted drugs and chemotherapeutics. The company seeks $1 million in investment to develop software for commercializing their product in Russia and expand into European markets starting in 2014.
The document announces the 2nd International Conference on Medicinal Chemistry & Computer Aided Drug Designing to be held from October 15-17, 2013 in Las Vegas, USA. The conference aims to bring together pharmaceutical companies, universities, biotech firms, government agencies and research institutions to share ideas and experiences in medicinal chemistry and drug designing. It will include presentations on the latest advances in these fields and encourage collaboration to foster innovation in drug development. Key speakers will discuss topics like rational drug design, computer-aided drug design, and quantitative structure-activity relationships.
Medicina Clinic has been developing since 1990 to improve patient care quality and adopt world's best practices. It is the first Russian clinic accredited by the Joint Commission International, meeting the highest global standards. The clinic aims to provide innovative, compassionate healthcare and social accountability through community support, research partnerships, and a charity foundation. It seeks continual improvement based on patient dialogue to establish the highest quality cancer center and set new standards for Russian healthcare.
The document provides an overview of the Northwest Cluster of the Medical and Pharmaceutical Industry, and Radiation Technologies located in St. Petersburg and Leningrad region of Russia. It notes that the Cluster has over 200 organizations including 40 R&D and 120 production entities and 59,000 total personnel. Key areas of focus for the Cluster include developing domestic medical products, equipment, nuclear technologies, and radiopharmaceutical products. The Cluster also has a large scientific potential through its universities and research institutions.
The document discusses Strand Genomics Inc., which offers genomic analysis and clinical interpretation software and services. It focuses on personalized medicine by using its StrandOmics platform to analyze genomic data and determine disease risks for individuals. StrandOmics aims to make genomic testing routine in medical care to help clinicians make more informed decisions. Strand has grown to over 200 scientists and serves over 2,000 labs and 100,000 patients. Its partnership with Health Care Global Enterprises successfully piloted cancer risk assessment and molecular diagnosis for over 50 patients in India.
Evotec and Oxford University announce a new partnership called LAB282 to accelerate early-stage biomedical research projects from Oxford into new therapeutics. LAB282 will be supported by a £13 million fund over 3 years and will select projects across any therapeutic area to help generate new treatments and spin-out companies. Evotec will contribute its drug discovery expertise and platforms and be entitled to equity in new companies formed from projects. The partnership combines academic and biotech strengths to efficiently translate science into new products.
Data-driven models for efficient diagnosis and disease management. From Academia to Startups.
Talk given at Crabb Lab Meeting, City University, London UK – Wed 23 August 2017
1. The pharmaceutical development process has low success rates, with less than 1 in 100,000 compounds tested making it to consumers and only 3 in 10 drugs earning back their average R&D costs.
2. Big pharma spends most of its R&D budget on late-stage clinical trials and regulatory costs. Outsourcing is increasingly used to access new technologies and markets.
3. The presentation discusses ChemRar's experience partnering with over 1200 companies globally over 20 years to conduct outsourced R&D and develop drugs through various stages from target identification to clinical trials.
RDIF, RCIF, and Middle Eastern investors will invest in the merger of JSC PE Obolenskoe and JSC Binnopharm to create one of the largest pharmaceutical companies in Russia. The merger aims to increase production capabilities, support research and development, and double sales over four years. It will facilitate the development of an R&D center to attract international biotech and pharmaceutical companies.
The IMI EHDEN project: large-scale analysis of observation data in Europe - C...Maxim Moinat
This document summarizes presentations from the CDISC 2020 Europe Interchange conference on April 1-2, 2020. It introduces Maxim Moinat who works on converting healthcare data to the OMOP Common Data Model. It also introduces Nigel Hughes who is the project lead for the IMI2 European Health Data & Evidence Network (EHDEN) and was previously involved in other real-world data projects. The document provides an agenda for the conference sessions which will discuss EHDEN, OHDSI, a EHDEN study-a-thon, using real-world data in clinical trials and for regulatory purposes.
Brochure | Case Reports Conference 2018 | London,UK | May 28-29 Ashley M. Benjamin
Euroscicon Ltd proudly presents the “8th International Conference on Clinical and Medical Case Reports, 2018” to be held on May 28-29, 2018 at London, UK.
This year’s theme is “Clinical and Medical Case Reports that pave way for an advanced healthcare”
Please visit the Conference website for more details : http://casereports.euroscicon.com/
Embedding impact in a Biomedical Research Centre through partnershipsPavel Ovseiko
The document discusses the NIHR Oxford Biomedical Research Centre (BRC) and its focus on partnerships. It makes the following key points:
1. The NIHR Oxford BRC is a partnership between Oxford University Hospitals NHS Foundation Trust and Oxford University. It has an annual budget of £20 million.
2. The BRC catalyzed partnerships across the wider health economy in Oxford. It has had impact through increasing clinical research funding and outputs for Oxford University.
3. A new theme within the BRC is focused on partnerships. It aims to strengthen partnerships and generate knowledge about research partnerships. Key partnerships discussed include those with patients, clinical services, industry, and policymakers.
This document contains information about biomedical clusters worldwide presented by Evgeniy Kutsenko at the National Research University Higher School of Economics in Moscow, Russia. It includes details about cluster initiatives and maps in Russia, characteristics and effects of biomedical clusters, criteria for evaluating clusters, groups of clusters identified in the research sample of 22 countries and 40 clusters, expert interviews with cluster managers, and key success factors of biomedical clusters according to the experts.
Horizon Discovery and Domainex Ltd have collaborated to support Domainex's TBK1/IKKε oncology research program. Under the agreement, Horizon will use its isogenic cell lines that model cancer mutations to profile Domainex's lead compounds. This will help identify which patient subgroups will respond and guide medicinal chemistry optimization. The collaboration will help efficiently develop a drug for this cancer target.
Fact sheet presenting the life sciences industry in the Quebec City region. Produced by Quebec International. http://quebecinternational.ca/key-industries/
Oxford PV was spun out of the University of Oxford in 2010 to commercialize solar cell technology developed by Professor Henry Snaith. The technology uses a material called perovskite that acts as a low-cost, highly efficient absorber to convert sunlight into electricity. It has potential advantages over traditional solar cells in being cheaper to produce, more efficient, semi-transparent, and able to be tuned to different colors. Oxford PV has grown to a team of over 30 people focused on developing this promising solar technology.
A consortium of investors, including the Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund), the Russia-China Investment Fund (RCIF, established by RDIF and China Investment Corporation), and leading Middle Eastern funds, have announced a 28% stake in Alium pharmaceutical holding.
The Russian Direct Investment Fund (RDIF), Russia’s sovereign wealth fund, announces that the RDIF and JBIC IG Partners, jointly advising the Russia-Japan Investment Fund (RJIF, established by RDIF, the Japan Bank for International Cooperation and JBIC IG Partners), have agreed, together with AEON Infrastructure Corporation, to collaborate on RJIF's planned investment to construct a methanol plant and create a chemical cluster in Volgograd.
More Related Content
Similar to RDIF invests in innovative cancer diagnostics developer Oncobox
The document summarizes the St. Petersburg International Forum on Pharmacy, Medical Equipment, and Biotechnology held in April 2012. Over 1,000 participants from Russia and abroad attended to discuss innovative development in the pharmaceutical, biotechnology, and medical industries. Key topics included attracting investment, introducing new technologies, and promoting locally made products internationally. The forum featured business programs, exhibitions, tours, and award ceremonies recognizing achievements in these fields. It aimed to facilitate cooperation to advance the regional medical and pharmaceutical cluster in St. Petersburg. Plans were announced for the next IPhEB forum to be held in April 2013.
RusGenDiagnostics Skolkovo Startup Village Pitch SessionElena Denisenko
RusGenDiagnostics develops diagnostic systems for personalized cancer treatment based on tumor molecular profiling using next-generation sequencing and microarrays. Their technology analyzes multiple genomic and transcriptomic alterations to reconstruct the individual tumor profile and evaluate targeted drugs and chemotherapeutics. The company seeks $1 million in investment to develop software for commercializing their product in Russia and expand into European markets starting in 2014.
The document announces the 2nd International Conference on Medicinal Chemistry & Computer Aided Drug Designing to be held from October 15-17, 2013 in Las Vegas, USA. The conference aims to bring together pharmaceutical companies, universities, biotech firms, government agencies and research institutions to share ideas and experiences in medicinal chemistry and drug designing. It will include presentations on the latest advances in these fields and encourage collaboration to foster innovation in drug development. Key speakers will discuss topics like rational drug design, computer-aided drug design, and quantitative structure-activity relationships.
Medicina Clinic has been developing since 1990 to improve patient care quality and adopt world's best practices. It is the first Russian clinic accredited by the Joint Commission International, meeting the highest global standards. The clinic aims to provide innovative, compassionate healthcare and social accountability through community support, research partnerships, and a charity foundation. It seeks continual improvement based on patient dialogue to establish the highest quality cancer center and set new standards for Russian healthcare.
The document provides an overview of the Northwest Cluster of the Medical and Pharmaceutical Industry, and Radiation Technologies located in St. Petersburg and Leningrad region of Russia. It notes that the Cluster has over 200 organizations including 40 R&D and 120 production entities and 59,000 total personnel. Key areas of focus for the Cluster include developing domestic medical products, equipment, nuclear technologies, and radiopharmaceutical products. The Cluster also has a large scientific potential through its universities and research institutions.
The document discusses Strand Genomics Inc., which offers genomic analysis and clinical interpretation software and services. It focuses on personalized medicine by using its StrandOmics platform to analyze genomic data and determine disease risks for individuals. StrandOmics aims to make genomic testing routine in medical care to help clinicians make more informed decisions. Strand has grown to over 200 scientists and serves over 2,000 labs and 100,000 patients. Its partnership with Health Care Global Enterprises successfully piloted cancer risk assessment and molecular diagnosis for over 50 patients in India.
Evotec and Oxford University announce a new partnership called LAB282 to accelerate early-stage biomedical research projects from Oxford into new therapeutics. LAB282 will be supported by a £13 million fund over 3 years and will select projects across any therapeutic area to help generate new treatments and spin-out companies. Evotec will contribute its drug discovery expertise and platforms and be entitled to equity in new companies formed from projects. The partnership combines academic and biotech strengths to efficiently translate science into new products.
Data-driven models for efficient diagnosis and disease management. From Academia to Startups.
Talk given at Crabb Lab Meeting, City University, London UK – Wed 23 August 2017
1. The pharmaceutical development process has low success rates, with less than 1 in 100,000 compounds tested making it to consumers and only 3 in 10 drugs earning back their average R&D costs.
2. Big pharma spends most of its R&D budget on late-stage clinical trials and regulatory costs. Outsourcing is increasingly used to access new technologies and markets.
3. The presentation discusses ChemRar's experience partnering with over 1200 companies globally over 20 years to conduct outsourced R&D and develop drugs through various stages from target identification to clinical trials.
RDIF, RCIF, and Middle Eastern investors will invest in the merger of JSC PE Obolenskoe and JSC Binnopharm to create one of the largest pharmaceutical companies in Russia. The merger aims to increase production capabilities, support research and development, and double sales over four years. It will facilitate the development of an R&D center to attract international biotech and pharmaceutical companies.
The IMI EHDEN project: large-scale analysis of observation data in Europe - C...Maxim Moinat
This document summarizes presentations from the CDISC 2020 Europe Interchange conference on April 1-2, 2020. It introduces Maxim Moinat who works on converting healthcare data to the OMOP Common Data Model. It also introduces Nigel Hughes who is the project lead for the IMI2 European Health Data & Evidence Network (EHDEN) and was previously involved in other real-world data projects. The document provides an agenda for the conference sessions which will discuss EHDEN, OHDSI, a EHDEN study-a-thon, using real-world data in clinical trials and for regulatory purposes.
Brochure | Case Reports Conference 2018 | London,UK | May 28-29 Ashley M. Benjamin
Euroscicon Ltd proudly presents the “8th International Conference on Clinical and Medical Case Reports, 2018” to be held on May 28-29, 2018 at London, UK.
This year’s theme is “Clinical and Medical Case Reports that pave way for an advanced healthcare”
Please visit the Conference website for more details : http://casereports.euroscicon.com/
Embedding impact in a Biomedical Research Centre through partnershipsPavel Ovseiko
The document discusses the NIHR Oxford Biomedical Research Centre (BRC) and its focus on partnerships. It makes the following key points:
1. The NIHR Oxford BRC is a partnership between Oxford University Hospitals NHS Foundation Trust and Oxford University. It has an annual budget of £20 million.
2. The BRC catalyzed partnerships across the wider health economy in Oxford. It has had impact through increasing clinical research funding and outputs for Oxford University.
3. A new theme within the BRC is focused on partnerships. It aims to strengthen partnerships and generate knowledge about research partnerships. Key partnerships discussed include those with patients, clinical services, industry, and policymakers.
This document contains information about biomedical clusters worldwide presented by Evgeniy Kutsenko at the National Research University Higher School of Economics in Moscow, Russia. It includes details about cluster initiatives and maps in Russia, characteristics and effects of biomedical clusters, criteria for evaluating clusters, groups of clusters identified in the research sample of 22 countries and 40 clusters, expert interviews with cluster managers, and key success factors of biomedical clusters according to the experts.
Horizon Discovery and Domainex Ltd have collaborated to support Domainex's TBK1/IKKε oncology research program. Under the agreement, Horizon will use its isogenic cell lines that model cancer mutations to profile Domainex's lead compounds. This will help identify which patient subgroups will respond and guide medicinal chemistry optimization. The collaboration will help efficiently develop a drug for this cancer target.
Fact sheet presenting the life sciences industry in the Quebec City region. Produced by Quebec International. http://quebecinternational.ca/key-industries/
Oxford PV was spun out of the University of Oxford in 2010 to commercialize solar cell technology developed by Professor Henry Snaith. The technology uses a material called perovskite that acts as a low-cost, highly efficient absorber to convert sunlight into electricity. It has potential advantages over traditional solar cells in being cheaper to produce, more efficient, semi-transparent, and able to be tuned to different colors. Oxford PV has grown to a team of over 30 people focused on developing this promising solar technology.
Similar to RDIF invests in innovative cancer diagnostics developer Oncobox (20)
A consortium of investors, including the Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund), the Russia-China Investment Fund (RCIF, established by RDIF and China Investment Corporation), and leading Middle Eastern funds, have announced a 28% stake in Alium pharmaceutical holding.
The Russian Direct Investment Fund (RDIF), Russia’s sovereign wealth fund, announces that the RDIF and JBIC IG Partners, jointly advising the Russia-Japan Investment Fund (RJIF, established by RDIF, the Japan Bank for International Cooperation and JBIC IG Partners), have agreed, together with AEON Infrastructure Corporation, to collaborate on RJIF's planned investment to construct a methanol plant and create a chemical cluster in Volgograd.
RDIF, Russia’s sovereign wealth fund, Mubadala Investment Company and other leading Middle Eastern investment funds announce the expansion of the Professional Logistics Technologies (PLT) platform with the construction of a new multi-temperature distribution centre, measuring more than 45.000 square meters, in PLT Chekhov industrial park.
A consortium of investors including the Russian Direct Investment Fund, Russia’s sovereign wealth fund, and a group of leading Middle Eastern funds, have announced the finalization of terms to participate in the construction project for the Startup Facility No. 4 of the Central Ring Road (СKAD-4).
The Russia-China Venture Fund (RCVF), the fund established in partnership between the Russia-China Investment Fund (RCIF) and the leading Chinese innovation-focused company Tus-Holdings, announces its first project. RCVF has agreed key terms of investment in Rusalox, a company producing innovative thermal conductive substrates.
RDIF, Russia’s sovereign wealth fund, and JSC Rosgeologia have announced an agreement to create an investment fund intended to provide venture financing for geological exploration.
RDIF, Russia’s sovereign wealth fund, announces a partnership with the State Atomic Energy Corporation Rosatom to implement a federal project "Developing facilities for safe handling of I-II hazard class waste”.
RDIF, Russia’s sovereign wealth fund, and The Federal Service for Supervision of Natural Resources announce their strategic cooperation for the implementation of investment projects contributing towards the intended targets set out in the government’s “Clean Air” project.
RDIF, Russia’s sovereign wealth fund, and the leading German wholesale-retailer METRO Cash & Carry announce the signing of an agreement aimed at investment support to the partners of the FASOL franchise program.
RDIF, Russia’s sovereign wealth fund, Bpifrance, France’s sovereign wealth fund, and Schneider Electric, the leader in digital transformation of energy management and automation have agreed on the main terms of a joint investment in energy-efficiency segment.
RDIF, Russia’s sovereign wealth fund, announces joint investments with leading Middle Eastern and Asia-Pacific funds in NefteTransService (NTS), one of the largest Russian operators of railway rolling stock.
A consortium of investors, including RDIF, Russia's sovereign wealth fund, Mubadala Investment Company (UAE), and other investors, including Baring Vostok Private Equity Fund IV, Flashpoint VC, RTP Global and Winter Capital, have reached an agreement to invest c.$40m in ivi, the leading Russian OTT Video on Demand service.
RDIF, Russia’s sovereign wealth fund, and China Investment Corporation (CIC) are to invest in a joint Russia-China Science and Technology Innovation Fund with a target capital of $1 billon.
A consortium of investors led by RDIF, Russia’s sovereign wealth fund, and a leading European meat producer Inalca announce a joint investment totaling over RUB1bn into the company’s Russian primary beef production operations.
RDIF, Russia’s sovereign wealth fund, announces a strategic partnership with China Energy Engineering Corporation (CEEC), one of the world’s leading providers of large scale power generation.
The Russian Direct Investment Fund (RDIF), along with Middle Eastern investors and JSC "GK Launch Services", will invest $87 million to modernize the infrastructure at Launch Pad No. 1 of the Baikonur Cosmodrome in Kazakhstan. The investment will help upgrade the facilities ahead of future launches of Soyuz-2 rockets, boosting the competitiveness of Russia's space industry. The modernization will attract new customers and support the development of the domestic space sector in Russia.
The Russian Direct Investment Fund (RDIF), Russia’s
sovereign wealth fund, has agreed the key terms of investments in Neurochat and
Neurotrend companies developing innovative products and solutions in the fields of
neurotechnology and artificial intelligence (AI).
The Russian Direct Investment Fund (RDIF), Russia’s
sovereign wealth fund, is investing up to RUB200 mn in Motorica, Russia’s leading
developer and producer of high-tech prosthetic appliances, which employs artificial
intelligence (AI).
RDIF and The State Hermitage Museum will present an exhibition “Artificial Intelligence and Intercultural Dialogue” dedicated to the creative capabilities of Artificial Intelligence.
The Russia-China Investment Fund, Suiyong Capital and Dazheng Investment Group have launched the China-Russia Regional RMB Fund and started analyzing potential projects.
ZKsync airdrop of 3.6 billion ZK tokens is scheduled by ZKsync for next week.pdfSOFTTECHHUB
The world of blockchain and decentralized technologies is about to witness a groundbreaking event. ZKsync, the pioneering Ethereum Layer 2 network, has announced the highly anticipated airdrop of its native token, ZK. This move marks a significant milestone in the protocol's journey, empowering the community to take the reins and shape the future of this revolutionary ecosystem.
World economy charts case study presented by a Big 4
World economy charts case study presented by a Big 4
World economy charts case
World economy charts case study presented by a Big 4
World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4
World economy charts case study presented by a Big 4
World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4study presented by a Big 4
UnityNet World Environment Day Abraham Project 2024 Press ReleaseLHelferty
June 12, 2024 UnityNet International (#UNI) World Environment Day Abraham Project 2024 Press Release from Markham / Mississauga, Ontario in the, Greater Tkaronto Bioregion, Canada in the North American Great Lakes Watersheds of North America (Turtle Island).
Methanex is the world's largest producer and supplier of methanol. We create value through our leadership in the global production, marketing and delivery of methanol to customers. View our latest Investor Presentation for more details.
The E-Way Bill revolutionizes logistics by digitizing the documentation of goods transport, ensuring transparency, tax compliance, and streamlined processes. This mandatory, electronic system reduces delays, enhances accountability, and combats tax evasion, benefiting businesses and authorities alike. Embrace the E-Way Bill for efficient, reliable transportation operations.
Cleades Robinson, a respected leader in Philadelphia's police force, is known for his diplomatic and tactful approach, fostering a strong community rapport.
RDIF invests in innovative cancer diagnostics developer Oncobox
1. RDIF invests in innovative cancer diagnostics developer Oncobox
Moscow, May 30, 2019 - The Russian Direct Investment Fund (RDIF), Russia’s
sovereign wealth fund, announces agreement on key terms of investments of
RUB100mn in Oncobox, a company developing solutions for cancer diagnosis based
on artificial intelligence (AI).
Oncobox is currently developing a digital platform for performing molecular
diagnostics of cancers. Instantly processing large amounts of patient data, the
platform’s AI selects optimal medications and effective treatment methods.
Oncobox products expand the range of tools that doctors can use to help prescribe the
correct course of therapy. Clinical studies have shown that Oncobox technology
increases the effectiveness of targeted chemotherapy for patients with advanced
cancer up to 70%.
Kirill Dmitriev, CEO of the RussianDirectInvestment Fund (RDIF), said:
“Oncobox is developing a unique product with an innovative approach to treatment.
The advances of artificial intelligence will make the cutting-edge medical
developments available to doctors around the world, significantly increasing patients’
chances of a successfulrecovery.”
Andrew Garazha, CEO of Oncobox, said:
“Oncobox has unique algorithms and databases that allow the most effective
treatment for each patient to be selected. With the support of the RDIF, we hope to
carry out a technological revolution in the standards of treatment for cancer patients,
providing the advances of modern molecular diagnostics and artificial intelligence.”
***
Russian Direct Investment Fund (RDIF) is Russia's sovereign wealth fund
established in 2011 to make equity co-investments, primarily in Russia, alongside
reputable international financial and strategic investors. RDIF acts as a catalyst for
direct investment in the Russian economy. RDIF’s management company is based in
Moscow. Currently, RDIF has experience of the successful joint implementation of
more than 70 projects with foreign partners totaling more than RUB 1.5tn and
2. covering 95% of the regions of the Russian Federation. RDIF portfolio companies
employ more than 700,000 people and generate revenues which equate to more than
5% of Russia’s GDP. RDIF established joint strategic partnerships with leading
international co-investors from more than 15 countries that total more than $40bn.
Further information can be found at www.rdif.ru
Oncobox was established in 2013, the scientific core of the project was based on
promising R&D products by scientists from Lomonosov Moscow State University,
Moscow Institute of Physics and Technology, and their colleagues from Germany. In
2016 the first clinical validation of the system at the University of Mainz was
completed with the support of the Innovation Promotion Fund. In 2017, Oncobox
became the first cancer diagnostics company using AI to be selected by the most
famous business accelerator in Silicon Valley, Y Combinator. The company conducts
registered clinical trials in Germany, Russia, and the USA, collaborates with leading
state and private cancer treatment centers. Since 2017, the company's employees have
published more than 30 articles in leading journals, including Nature Scientific Data,
Seminars in Cancer Biology and Frontiers in Oncology. Further information can be
found at https://oncobox.com/
For additional information contact:
Arseniy Palagin Maria Shiryaevskaya/ Andrew Leach
Russian Direct Investment Fund Hudson Sandler
Press Secretary Tel: +44 (0) 20 7796 4133
Tel: +7 495 644 34 14, ext. 2395
Mobile: +7 916 110 31 41
E-mail: arseniy.palagin@rdif.ru